Operating Lease, Right-of-Use Asset of Ovid Therapeutics Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of lessee's right to use underlying asset under operating lease.
Summary: Ovid Therapeutics Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
Ovid Therapeutics Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $11,916,000, a 8.9% decline year-over-year.
Source SEC data: View on sec.gov

Operating Lease, Right-of-Use Asset, Quarterly (USD)

Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Ovid Therapeutics Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$11,916,000	-$1,164,000	-8.9%	30 Sep 2025	10-Q	12 Nov 2025	2025	Q3
Q2 2025	$12,215,000	-$1,142,000	-8.6%	30 Jun 2025	10-Q	13 Aug 2025	2025	Q2
Q1 2025	$12,509,000	-$1,119,000	-8.2%	31 Mar 2025	10-Q	13 May 2025	2025	Q1
Q4 2024	$12,797,000	-$1,097,000	-7.9%	31 Dec 2024	10-Q	12 Nov 2025	2025	Q3
Q3 2024	$13,080,000	-$1,075,246	-7.6%	30 Sep 2024	10-Q	12 Nov 2024	2024	Q3
Q2 2024	$13,357,000	-$1,055,068	-7.3%	30 Jun 2024	10-Q	13 Aug 2024	2024	Q2
Q1 2024	$13,628,000	-$1,041,362	-7.1%	31 Mar 2024	10-Q	14 May 2024	2024	Q1
Q4 2023	$13,894,000	-$1,028,669	-6.9%	31 Dec 2023	10-K	11 Mar 2025	2024	FY
Q3 2023	$14,155,246	-$1,022,393	-6.7%	30 Sep 2023	10-Q	03 Nov 2023	2023	Q3
Q2 2023	$14,412,068	-$1,025,516	-6.6%	30 Jun 2023	10-Q	04 Aug 2023	2023	Q2
Q1 2023	$14,669,362	-$1,022,120	-6.5%	31 Mar 2023	10-Q	05 May 2023	2023	Q1
Q4 2022	$14,922,669	+$14,922,669		31 Dec 2022	10-K	08 Mar 2024	2023	FY
Q3 2022	$15,177,639			30 Sep 2022	10-Q	08 Nov 2022	2022	Q3
Q2 2022	$15,437,584			30 Jun 2022	10-Q	09 Aug 2022	2022	Q2
Q1 2022	$15,691,482			31 Mar 2022	10-Q	10 May 2022	2022	Q1
Q4 2021	$0			31 Dec 2021	10-K	13 Mar 2023	2022	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.